As the landscape of biotechnology expands rapidly across India, a significant and potentially precarious legal vacuum has emerged regarding the ownership of genetic information. With ancestry platforms, clinical diagnostics, and law enforcement databases now routinely processing the biological blueprints of millions, the absence of a defined legal framework for " genetic property " is placing individual rights at risk. This lack of oversight has transformed what was once a niche concern for bioethicists into a pressing legal crisis that now permeates corporate boardrooms, police stations, and diagnostic laboratories, leaving citizens without clear recourse when their genetic data is commodified.

The urgency of this situation is underscored by the recurring shadow of international precedents, most notably the 1990 case of Moore v. Regents of University of California . In that landmark litigation, John Moore discovered that his doctors at the University of California had harvested his cells after a 1980 splenectomy to create a commercially lucrative cell line. Despite the multi-million-dollar licensing revenue generated by his biological material, the court ruled that Moore lacked the legal standing to claim ownership over his excised tissue. While he could pursue action for a breach of fiduciary duty , the foundational principle of biological property remained out of reach. India’s current legal architecture, critics argue, is moving toward a similarly silent, if not more restrictive, outcome.

The Legislative Silence in Indian Bio-Governance

The current predicament is characterized by a series of legislative omissions that create a fragmented and largely unprotected environment for genetic data. Indian data protection statutes, while ambitious in scope, do not adequately categorize genetic information as distinctively sensitive in a manner that would trigger heightened protections or ownership rights. Simultaneously, traditional property laws in the country remain tethered to an archaic framework designed for land and tangible consumer goods, leaving the intangible yet hyper-personal nature of genetic code in a legal gray zone.

This systemic silence manifests across multiple sectors. Under current transplantation laws, for instance, genetic testing is often mandated for medical procedures without the necessary disclosure protocols that would inform a donor or patient about how their subsequent data might be stored, analyzed, or sold. Furthermore, the architecture governing criminal investigations allows for the near-indefinite retention of DNA profiles within state-run databases, yet these systems operate without an independent, robust oversight board to monitor potential misuse or unauthorized access. These are not merely administrative lapses; they represent a fundamental vacuum where the law effectively vacates the premises, leaving the individual exposed to the commercial and state-led exploitation of their most intimate data.

Navigating the Property Law Dead End

When legal scholars and advocates attempt to resolve these disputes, the immediate instinct is to look toward property law . The intuitive argument is that if a strand of DNA belongs to an individual, it should function as personal property —a resource that can be owned, transferred, or withheld from others at the owner's discretion. However, applying this framework has proven historically difficult in global jurisprudence. Treating biological data as a commodity creates a slippery slope; if genetic information is property, does it then become an asset that can be seized in bankruptcy or sold as collateral? The commercialization of biological data requires a balance between incentivizing medical research and protecting the fundamental autonomy of the individual.

In the Indian context, the absence of a specific legislative response means that researchers and corporations are often left to operate under self-regulated ethical guidelines rather than binding statutory obligations. This creates an environment of significant variability in how patient samples are handled. As one observer noted, "The question of who owns your DNA has migrated from bioethics seminars into courtrooms, boardrooms, and police stations. There is no clear answer in Indian law." Without a legislative intervention, the default position remains one where those who control the diagnostic and research infrastructure exert de facto ownership , effectively silencing the donor's right to claim any stake in the commercial successes derived from their own biological makeup.

Emerging Risks in the Digital Age

The proliferation of ancestry and health-tracking services has introduced a new layer of risk that was unimaginable even a decade ago. These platforms often require users to sign lengthy, complex terms of service agreements that grant the company wide-ranging rights to utilize, store, and potentially share genetic data with third-party researchers or corporate partners. Because the law in India has not yet declared genetic data to be a protected class of personal property , these "consent" agreements often function as an absolute waiver of rights, even when the implications of such a waiver are not fully understood by the average consumer.

The intersection of these services with the broader clinical and forensic landscape creates a ecosystem where the boundaries of ownership are increasingly blurred. If a person provides a DNA sample for a wellness program, it is currently unclear if that same sample could theoretically be accessed by law enforcement or pharmaceutical developers without further, specific, and transparent consent. As the country moves toward a more digitized health infrastructure, the risk of a "Moore moment"—a high-profile case where an individual’s genetic data yields significant profit while the donor is relegated to the sidelines of the transaction—becomes increasingly likely.

Legal experts suggest that the solution must move beyond traditional concepts of ownership. Instead, there is a mounting call for a " data sovereignty " model that emphasizes individual control and ongoing consent rather than simple commodification. This would involve creating strict mandates for how biological data is de-identified, stored, and re-used, while ensuring that the donor maintains the right to withdraw access at any time. As the legislative session approaches, the demand for a clear, modernized framework—one that treats genetic material as an extension of the person rather than as raw material for the industrial market—remains the most significant hurdle for policymakers. Until such a framework is enacted, the current state of regulatory uncertainty continues to leave the citizenry vulnerable to the opaque and often irreversible use of their own biological identities.